BofA lowered the firm’s price target on GoodRx (GDRX) to $3 from $3.40 and keeps an Underperform rating on the shares after the company announced two initiatives for its weight loss offering. BofA sees the announcement positively as the collaboration builds on GoodRx’s existing partnership with Novo Nordisk and further expands the subscription offering, the firm told investors. BofA acknowledged the progress that GoodRx is making to expand partnerships but maintained its Underperform rating given broader headwinds from pharmacy closures and reimbursement changes in the pharmacy ecosystem.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx announces weight loss telemedicine subscription, Novo Nordisk pact
- Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month
- GoodRx price target lowered to $5 from $6 at JPMorgan
- GoodRx price target lowered to $6 from $7 at TD Cowen
- Trump Weekly: China to suspend some controls on rare earths